TopoGEN, Inc.
Products and Services for Cancer Research
Products and Services for Cancer Research
TopoGEN, Inc. is a biotechnology company specializing in products and services for cancer research. Founded in 1991, the company caters to the needs of researchers working with topoisomerases and involved in mechanism-based drug discovery and development. Their top-selling products include Drug Screening Kits, Assay Kits for assaying prokaryotic and eukaryotic topoisomerases, and a complete line of DNA substrates and DNA cleavage targets, among others. Notably, TopoGEN offers contract screening services with custom screens developed entirely in-house, establishing their expertise in cancer research.
The company received a $100.00K grant investment on 18 May 2023 from the Advanced Industries Accelerator (AIA) Program. With a dedicated global clientele since the early 1990s, TopoGEN emphasizes substantial product support, data interpretation, and consultation advice, positioning themselves as research partners for their customers. As they continue to contribute to the advancement of cancer research, TopoGEN presents an attractive investment opportunity within the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $100.00K | 1 | Advanced Industries Accelerator (AIA) Program | 18 May 2023 |
No recent news or press coverage available for TopoGEN, Inc..
We care about your data, and we'd love to use cookies make your experience better.